Heidelberg, Baden-Württemberg, Germany
The promise of Precision Medicine Biology. The biggest 'risk' in medicine. Why? Because biology of health and disease is not well understood. - To understand one needs data. Of the patient, and of populations. Longitudinally = over time. - To be as precise as possible one needs molecular data: the genome, first sequenced in 2001 and routinely available today, and other 'omes' which are in part not yet routine today. - To make use one needs to curate and integrate these heterogeneous data types to allow to process them. - To contextualize one needs scientific computing. - To understand one needs analytics including AI. Rich and clean data in combination with AI will transform outcome of care and success of drug development. - For better care: better diagnosis, better therapy decision support, better learning. - For more effective and efficient drug development: better drug-disease understanding -> better clinical trial planning -> better patient selection -> smaller and faster trials & lower attrition rates: better biomarkers and drugs faster and cheaper to the market. - For better disease prevention. This is the combined molecular clinical-scientific computing-based transformation of healthcare. Worldwide. The promise of Precision Medicine!
Co-Founder, 2004, and since 2016 CEO of Molecular Health
Co-Founder of dievini Hopp BioTec holding GmbH & Co. KG together with Dietmar Hopp and Christof Hettich.